FDA Inspection
Continental Services Group, Inc.Continental Services Group, Inc. – FDA Inspection, Aug 22, 2017
Record Details
This FDA Inspection record concerns Continental Services Group, Inc., with an inspection on August 22, 2017, issued by the Center for Biologics Evaluation and Research, covering biologics.
View Company Profile
ID · 7f1d4708-484f-4a85-b019-598b8d1f7b0f
Inspection Facts
Voluntary Action Indicated (VAI)
Objectionable conditions were found, but FDA is not prepared to take or recommend regulatory action.
- Inspection number
- 1023396
- FDA center
- Biologics
- Project area
- Blood and Blood Products
- Outcome
- Form 483 issued
FDA Citations
3- 21 CFR 640.65(b)(1)(iii)Greater than six months since four month sample
- 21 CFR 606.40(a)(1)Provide space for examination
- 21 CFR 606.170(a)Adverse Reaction- Reports of Investigations
Full citation text and observation details available on the Dashboard.
Other FDA inspections of Continental Services Group, Inc.
4| Date | Classification | Office | Project area |
|---|---|---|---|
| June 29, 2026 | Not classified | Florida District Office | Blood and Blood Products |
| May 21, 2024 | VAI | Florida District Office | Blood and Blood Products |
| August 24, 2022 | NAI | Center for Biologics Evaluation and Research | Vaccines and Allergenic Products |
| July 9, 2019 | VAI | Center for Biologics Evaluation and Research | Blood and Blood Products |
Other documents for Continental Services Group, Inc.
- FDA Inspection 1326644 - 2026-06-29
- FDA Inspection 1239104 - 2024-05-21
- FDA Inspection 1178110 - 2022-08-24
- FDA Inspection 1096414 - 2019-07-09
Document or profile
One record shows the event. A profile shows the pattern.
Buy this document for the source file and details behind this single event.
Choose full profile access to connect related records, sites, people, citations, and enforcement history in one view.